title: GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples.
abstract: The purpose of this study was to evaluate the GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) for its ability to detect resistance to rifampin (RIF) and isoniazid (INH) in Mycobacterium tuberculosis clinical strains and directly in clinical samples. A total of 62 clinical strains characterized with the Bactec 460TB system were included. For the INH-resistant strains, the MIC was measured and sequencing was performed. Sixty-five clinical samples from 28 patients (39 smear-positive samples and 26 smear-negative samples) were also tested directly. The corresponding isolates of the clinical specimens were studied with the Bactec 460TB system. The overall rates of concordance of the MTBDRplus assay and the Bactec 460TB system for the detection of RIF and INH susceptibility in clinical strains were 98.3% (61/62) and 79% (49/62), respectively. The rate of concordance between the Bactec 460TB system and the MTBDRplus test for the detection of INH resistance in the group of 27 strains with low-level resistance was 62.9% (17/27), and that for the detection of INH resistance in the group of 21 strains with high-level resistance was 85.71% (18/21). Valid test results were obtained for 78.45% (51/65) of the clinical samples tested. The rates of concordance between both assays for the detection of drug resistance in these samples were 98% (50/51) for RIF and 96.2% (49/51) for INH. Taking into account only one sample per patient, the overall rate of concordance between both tests was 92.85% (26/28). The GenoType MTBDRplus assay is easy to perform and is a useful tool for the management of tuberculosis, as it allows the detection of resistance to RIF and INH in M. tuberculosis strains and also in clinical samples.
authors.affiliation: Servei de Microbiologia, Fundació Institut en Ciències de la Salut Germans Trias i Pujol, Carretera del Canyet s/n, Badalona 08916, Barcelona, Spain. jadomb@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: Lacoma
authors.forename: N
authors.initials: N
authors.lastname: Garcia-Sierra
authors.forename: C
authors.initials: C
authors.lastname: Prat
authors.forename: J
authors.initials: J
authors.lastname: Ruiz-Manzano
authors.forename: L
authors.initials: L
authors.lastname: Haba
authors.forename: S
authors.initials: S
authors.lastname: Rosés
authors.forename: J
authors.initials: J
authors.lastname: Maldonado
authors.forename: J
authors.initials: J
authors.lastname: Domínguez
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D001431:Bacteriological Techniques / Q000379:methods*; D004269:DNA, Bacterial / Q000235:genetics*; D004351:Drug Resistance; D005838:Genotype; D005858:Germany; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D011237:Predictive Value of Tests; D012293:Rifampin / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D017422:Sequence Analysis, DNA; D014376:Tuberculosis / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D004269:DNA, Bacterial; D007538:Isoniazid; D012293:Rifampin
references.citation: Microb Drug Resist. 2005 Summer;11(2):107-14
references.pmid: 15910223
references.citation: J Clin Microbiol. 2001 Jan;39(1):107-10
references.pmid: 11136757
references.citation: J Infect Dis. 2000 Dec;182(6):1788-90
references.pmid: 11069256
references.citation: Eur J Clin Microbiol Infect Dis. 2007 Jan;26(1):51-5
references.pmid: 17180347
references.citation: J Clin Microbiol. 2006 Jan;44(1):201-5
references.pmid: 16390970
references.citation: Science. 1993 May 7;260(5109):819-22
references.pmid: 8484123
references.citation: Br Med Bull. 1984 Jan;40(1):84-90
references.pmid: 6442876
references.citation: Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):189-92
references.pmid: 9665301
references.citation: J Clin Microbiol. 2007 Aug;45(8):2635-40
references.pmid: 17537937
references.citation: J Clin Microbiol. 2006 Jul;44(7):2605-8
references.pmid: 16825393
references.citation: Am Rev Respir Dis. 1988 May;137(5):1217-22
references.pmid: 3195815
references.citation: Antimicrob Agents Chemother. 2003 Apr;47(4):1241-50
references.pmid: 12654653
references.citation: J Clin Microbiol. 2006 Feb;44(2):350-2
references.pmid: 16455882
references.citation: Tuber Lung Dis. 1998;79(1):3-29
references.pmid: 10645439
references.citation: J Clin Microbiol. 2008 Jan;46(1):393-4
references.pmid: 17977988
references.citation: J Antimicrob Chemother. 2005 Jun;55(6):860-5
references.pmid: 15879493
references.citation: Lancet. 1993 Mar 13;341(8846):647-50
references.pmid: 8095569
references.citation: Clin Microbiol Infect. 2007 Dec;13(12):1144-56
references.pmid: 17727670
references.citation: J Clin Microbiol. 2006 Jul;44(7):2338-42
references.pmid: 16825346
references.citation: Emerg Infect Dis. 1998 Apr-Jun;4(2):195-209
references.pmid: 9621190
references.citation: Clin Microbiol Infect. 2005 Feb;11(2):122-30
references.pmid: 15679486
references.citation: Respir Res. 2001;2(3):164-8
references.pmid: 11686881
references.citation: J Clin Microbiol. 2006 Oct;44(10):3659-64
references.pmid: 17021094
references.citation: J Clin Microbiol. 2003 Jun;41(6):2647-9
references.pmid: 12791894
references.citation: J Clin Microbiol. 2005 Aug;43(8):3699-703
references.pmid: 16081898
references.citation: J Clin Microbiol. 2006 Jul;44(7):2485-91
references.pmid: 16825369